A novel urethral sparing technique for high-dose-rate prostate brachytherapy after transurethral resection of the prostate

被引:0
|
作者
Kunogi, Hiroaki [1 ,2 ]
Cunha, Jason Adam M. [1 ]
Chang, Albert J. [1 ]
Gadzinski, Adam J. [3 ]
Shinohara, Katsuto [3 ]
Hsu, I-Chow [1 ]
机构
[1] Univ Calif San Francisco, Dept Radiat Oncol, 1600 Divisadero St,H1031, San Francisco, CA 94143 USA
[2] Juntendo Univ, Dept Radiat Oncol, Bunkyo Ku, Tokyo, Japan
[3] Univ Calif San Francisco, Dept Urol, San Francisco, CA USA
关键词
Brachytherapy; HDR; Prostate; TURP; Urinary catheter; CANCER; RADIOTHERAPY; TOXICITY;
D O I
10.1016/j.brachy.2017.07.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE: The purpose of this study was to assess retrospectively the variability of the urethral dose optimized using a Foley catheter versus urethral contrast injected using a new modified triple-lumen catheter, in CT-based high-dose-rate (HDR) prostate brachytherapy of posttransurethral resection of prostate (TURP) patients. METHODS AND MATERIALS: At our institution, there were six post-TURP patients with prostate carcinoma between July 2014 and April 2016 who underwent transperineal interstitial HDR brachytherapy (16 needles). A custom modified triple-lumen catheter was placed to inject contrast into the TURP defect. Three-dimensional optimal plans using inverse planning simulated annealing algorithm was generated according to radiation therapy oncology group dose requirements. Alternative plans were retroactively generated for comparison using standard technique based on a Foley catheter as a urethral constraint volume for each patient with the same weighting factors. We compared the dosimetry parameters in each planning using Wilcoxon's ranked sum nonparametric test. RESULTS: The median followup of all patients was 17.5 months. No significant genitourinary or gastrointestinal toxicity was noted using this technique. In the dosimetric analysis, the prostate V-100 values and TURP urethral V100 were significantly different between plans with and without the contrast (V100 [mean]: 92.4 [%] vs. 94.4 [%], p = 0.046; TURP UV100 [mean]: 1.4 cc vs. 2.2 cc, p = 0.028). There were no statistical differences in the mean values of planning target volume V-150%, V(20)0%, and D-90, and each bladder V-75 and rectum (V75). CONCLUSIONS: Post-TURP HDR brachytherapy with urethral contrast showed significantly more volume effect of the TURP defect than that with a Foley catheter alone. Better visualization of the TURP defect should lead to more accurate urethral sparing administration of HDR brachytherapy which is necessary to prevent urethral complication. (C) 2017 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1113 / 1118
页数:6
相关论文
共 50 条
  • [1] A dosimetric evaluation of a single urethral constraint for high-dose-rate prostate brachytherapy
    Lu, Diana J.
    Phillips, Tiffany
    DeMarco, John
    Sandler, Howard M.
    Kamrava, Mitchell
    BRACHYTHERAPY, 2020, 19 (02) : 216 - 221
  • [2] High dose rate transurethral brachytherapy as a boost dose for localized adenocarcinoma of the prostate
    Serin, M
    Erkal, HS
    Sak, SD
    Cakmak, A
    Gogus, O
    Akkaya, A
    UROLOGIA INTERNATIONALIS, 1997, 58 (01) : 30 - 33
  • [3] Complications and side effects of high-dose-rate prostate brachytherapy
    Martell, Kevin
    Kollmeier, Marisa A.
    BRACHYTHERAPY, 2021, 20 (05) : 966 - 975
  • [4] Open MR-Guided High-Dose-Rate (HDR) Prostate Brachytherapy: Feasibility and Initial Experiences Open MR-Guided High-Dose-Rate (HDR) Prostate Brachytherapy
    Lakosi, Ferenc
    Antal, Gergely
    Vandulek, Csaba
    Kovacs, Arpad
    Toller, Gabor L.
    Rakasz, Istvan
    Bajzik, Gabor
    Hadjiev, Janaki
    Bogner, Peter
    Repa, Imre
    PATHOLOGY & ONCOLOGY RESEARCH, 2011, 17 (02) : 315 - 324
  • [5] High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience
    Jabbari, Siavash
    Hsu, I. -Chow
    Kawakami, Jun
    Weinberg, Vivian K.
    Speight, Joycelyn L.
    Gottschalk, Alexander R.
    Roach, Mack, III
    Shinohara, Katsuto
    BRACHYTHERAPY, 2009, 8 (04) : 339 - 344
  • [6] Previous transurethral resection of the prostate is not a contraindication to high-dose rate brachytherapy for prostate cancer
    Luo, Hao Lun
    Fang, Fu Min
    Chuang, Yao Chi
    Chiang, Po Hui
    BJU INTERNATIONAL, 2009, 104 (11) : 1620 - 1623
  • [7] Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer
    Barnes, Justin
    Kennedy, William R.
    Fischer-Valuck, Benjamin W.
    Baumann, Brian C.
    Michalski, Jeff M.
    Gay, Hiram A.
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2019, 11 (04) : 320 - 328
  • [8] ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer
    Hsu, I-Chow Joe
    Yamada, Yoshiya
    Assimos, Dean G.
    D'Amico, Anthony V.
    Davis, Brian J.
    Frank, Steven J.
    Gottschalk, Alexander R.
    Gustafson, Gary S.
    McLaughlin, Patrick W.
    Nguyen, Paul L.
    Rosenthal, Seth A.
    Taira, Al V.
    Vapiwala, Neha
    Merrick, Gregory
    BRACHYTHERAPY, 2014, 13 (01) : 27 - 31
  • [9] Dosimetric coverage of the prostate, normal tissue sparing, and acute toxicity with high-dose-rate brachytherapy for large prostate volumes
    Yang, George
    Strom, Tobin J.
    Wilder, Richard B.
    Shrinath, Kushagra
    Mellon, Eric A.
    Fernandez, Daniel C.
    Biagioli, Matthew C.
    INTERNATIONAL BRAZ J UROL, 2015, 41 (03): : 435 - 441
  • [10] Low morbidity following high dose rate brachytherapy in the setting of prior transurethral prostate resection
    Peddada, Anuj V.
    Jennings, Scott B.
    Faricy, Patrick O.
    Walsh, Richard A., III
    White, Gerald A.
    Monroe, Alan T.
    JOURNAL OF UROLOGY, 2007, 178 (05) : 1963 - 1967